Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$0.14 - $0.27 $4,504 - $8,687
-32,177 Reduced 49.58%
32,720 $4,000
Q3 2023

Nov 09, 2023

SELL
$0.17 - $3.0 $1,664 - $29,370
-9,790 Reduced 13.11%
64,897 $11,000
Q2 2023

Aug 09, 2023

BUY
$2.5 - $3.42 $186,717 - $255,429
74,687 New
74,687 $233,000
Q4 2022

Feb 09, 2023

BUY
$1.34 - $1.78 $3,430 - $4,556
2,560 Added 300.12%
3,413 $5,000
Q3 2022

Nov 09, 2022

BUY
$1.15 - $2.1 $980 - $1,791
853 New
853 $1,000
Q2 2022

Aug 11, 2022

SELL
$1.24 - $2.39 $42,597 - $82,103
-34,353 Closed
0 $0
Q1 2022

May 12, 2022

SELL
$2.01 - $4.19 $68,926 - $143,683
-34,292 Reduced 49.96%
34,353 $82,000
Q4 2021

Feb 11, 2022

BUY
$1.27 - $8.28 $87,179 - $568,380
68,645 New
68,645 $315,000

Others Institutions Holding GRTX

About Galera Therapeutics, Inc.


  • Ticker GRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,821,600
  • Market Cap $1.07M
  • Description
  • Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical tria...
More about GRTX
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.